Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | HTT | P42858 | 3/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.45 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.45 |
| ▸ | PTPN6 | P29350 | 2/20 | 0.45 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.45 |
| ▸ | PTPRF | P10586 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | ESRRA | P11474 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20471165 | 0.89 | S1PR3 (0.48) | SMN1; SMN2ALDH1A1HTTTSHRLMNA | |
| SCHEMBL4005176 | 0.89 | LMNA (0.45) | SMN1; SMN2ALDH1A1HTTTSHRLMNA | |
| SCHEMBL1547097 | 0.89 | TDP1 (0.57) | SMN1; SMN2ALDH1A1HTTTSHRLMNA | |
| SCHEMBL29017032 | 0.87 | HTT (0.52) | SMN1; SMN2ALDH1A1HTTTSHRLMNA | |
| SCHEMBL6628635 | 0.87 | HTT (0.52) | SMN1; SMN2ALDH1A1HTTTSHRLMNA | |
| SCHEMBL30823666 | 0.85 | S1PR3 (0.56) | ALDH1A1HTTTSHRLMNAMAPK1 | |
| SCHEMBL4268302 | 0.85 | S1PR3 (0.56) | ALDH1A1HTTTSHRLMNAMAPK1 | |
| SCHEMBL15352924 | 0.85 | GAA (0.52) | SMN1; SMN2ALDH1A1TSHRLMNAMAPK1 | |
| SCHEMBL14822815 | 0.84 | MAPK1 (0.60) | SMN1; SMN2ALDH1A1HTTTSHRLMNA | |
| SCHEMBL4897962 | 0.81 | ALDH1A1 (0.51) | SMN1; SMN2ALDH1A1TSHRLMNATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10654837-B2 | Sulphamoylaryl derivatives and use thereof as medicaments for the treatment of liver fibrosis | JANSSEN PHARMACEUTICA NV (BE) | 2020-05-19 | — | — | US | disclosed |
| US-10654837-B2 | Sulphamoylaryl derivatives and use thereof as medicaments for the treatment of liver fibrosis | JANSSEN PHARMACEUTICA NV (BE) | 2020-05-19 | — | — | US | disclosed |
| US-20190345145-A1 | SULPHAMOYLARYL DERIVATIVES AND USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF LIVER FIBROSIS | JOHNSON & JOHNSON (CHINA) INVESTMENT LTD. (CN) | 2019-11-14 | — | — | US | disclosed |
| US-20190345145-A1 | SULPHAMOYLARYL DERIVATIVES AND USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF LIVER FIBROSIS | JOHNSON & JOHNSON (CHINA) INVESTMENT LTD. (CN) | 2019-11-14 | — | — | US | disclosed |
| CN-1149206-C | Intermediate compound for preparing xibo ketone | ������ҩ������˾ | 2004-05-12 | — | — | CN | disclosed |
| EP-0916675-B1 | Process for preparing sildenafil | PFIZER LTD (GB) | 2003-07-30 | — | — | EP | disclosed |
| CN-1106399-C | Process for preparing sildenafil | PFIZER RES & DEV (IE) | 2003-04-23 | — | — | CN | disclosed |
| WO-2002016364-A1 | POLYETHOXYLATED PYRAZOLO PYRIMIDINONE DERIVATIVES, PROCESS FOR PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME FOR THE TREATMENT OF IMPOTENCE | LG LIFE SCIENCES LTD. (KR) | 2002-02-28 | — | — | WO | disclosed |
| US-6066735-A | TREATMENT OF ERECTILE DYSFUNCTION | PFIZER INC. (US) | 2000-05-23 | — | — | US | disclosed |
| US-5955611-A | CYCLIZATION OF DIAMIDEPYRAZOLE TO FORM PYRIMIDONE OF PYRAZOLE | PFIZER INC. (US) | 1999-09-21 | — | — | US | disclosed |
| EP-0812845-B1 | Process for preparing sildenafil | PFIZER LTD (GB) | 1999-07-14 | — | — | EP | disclosed |
| EP-0916675-A2 | Process for preparing sildenafil | Pfizer Limited (GB) | 1999-05-19 | — | — | EP | disclosed |
| EP-0812845-A1 | Process for preparing sildenafil | Pfizer Limited (GB) | 1997-12-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10654837-B2 | Sulphamoylaryl derivatives and use thereof as medicaments for the treatment of liver fibrosis | HTR2B, HTR3B, HTR1A | SMN1; SMN2 4266/4885ALDH1A1 181/4885HTT 2782/4885 |
| US-20190345145-A1 | SULPHAMOYLARYL DERIVATIVES AND USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF LIVER FIBROSIS | HTR2B, HTR3B, HTR1A | SMN1; SMN2 4266/4885ALDH1A1 181/4885HTT 2782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.